Jia Jie Biomedical Co., Ltd. (TPEX:4109)
Taiwan · Delayed Price · Currency is TWD 13.70
-0.05 (-0.36%)
Feb 11, 2026, 1:30 PM CST
Jia Jie Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 482.03 | 537.07 | 332.76 | 317.72 | 242.48 | 270.29 | |
Revenue Growth (YoY) | -1.86% | 61.40% | 4.73% | 31.03% | -10.29% | -21.21% |
Cost of Revenue | 322.07 | 363.72 | 215.12 | 201.21 | 158.71 | 228.58 |
Gross Profit | 159.97 | 173.35 | 117.64 | 116.51 | 83.77 | 41.71 |
Selling, General & Admin | 132.5 | 133.58 | 174.79 | 121.96 | 81.39 | 89.87 |
Research & Development | 6.07 | 6.55 | 9.32 | 8.94 | 3.61 | 0.17 |
Operating Expenses | 138.58 | 140.18 | 183.84 | 130.19 | 84.7 | 90.05 |
Operating Income | 21.39 | 33.17 | -66.2 | -13.68 | -0.93 | -48.33 |
Interest Expense | -0.2 | -0.64 | -0.35 | -0.11 | -0.06 | -0.71 |
Interest & Investment Income | 10.27 | 3.49 | 6.76 | 3.83 | 0.59 | 0.1 |
Earnings From Equity Investments | - | - | 0.31 | - | - | - |
Currency Exchange Gain (Loss) | 0.06 | 0.47 | 0.29 | -0.29 | -0.49 | 0.36 |
Other Non Operating Income (Expenses) | 7.77 | 5.83 | 5.61 | 5.07 | 4.19 | 3.49 |
EBT Excluding Unusual Items | 39.28 | 42.32 | -53.59 | -5.19 | 3.3 | -45.09 |
Gain (Loss) on Sale of Investments | -17.05 | 183.75 | 200.25 | - | - | - |
Gain (Loss) on Sale of Assets | - | -0.58 | -0.12 | 0.48 | -0.53 | -0.27 |
Other Unusual Items | - | - | 0.01 | 0.04 | 2.52 | 3.71 |
Pretax Income | 22.24 | 225.49 | 146.55 | -4.68 | 5.29 | -41.65 |
Income Tax Expense | 15.84 | 9.34 | -0.48 | 1.76 | 0.19 | -8.96 |
Earnings From Continuing Operations | 6.4 | 216.15 | 147.02 | -6.44 | 5.1 | -32.7 |
Minority Interest in Earnings | -3.14 | -4.78 | -2.88 | 0.97 | 0.24 | 0.77 |
Net Income | 3.26 | 211.37 | 144.15 | -5.47 | 5.34 | -31.93 |
Net Income to Common | 3.26 | 211.37 | 144.15 | -5.47 | 5.34 | -31.93 |
Net Income Growth | -99.17% | 46.64% | - | - | - | - |
Shares Outstanding (Basic) | 111 | 98 | 89 | 89 | 89 | 69 |
Shares Outstanding (Diluted) | 112 | 98 | 89 | 89 | 89 | 69 |
Shares Change (YoY) | 16.11% | 10.08% | 0.29% | - | 28.10% | 0.71% |
EPS (Basic) | 0.03 | 2.16 | 1.62 | -0.06 | 0.06 | -0.46 |
EPS (Diluted) | 0.03 | 2.15 | 1.62 | -0.06 | 0.06 | -0.46 |
EPS Growth | -99.38% | 32.72% | - | - | - | - |
Free Cash Flow | -43.23 | 24.72 | -13.1 | -26.64 | 2.85 | 25.47 |
Free Cash Flow Per Share | -0.39 | 0.25 | -0.15 | -0.30 | 0.03 | 0.37 |
Dividend Per Share | 0.500 | 0.500 | 0.500 | - | - | - |
Gross Margin | 33.19% | 32.28% | 35.35% | 36.67% | 34.55% | 15.43% |
Operating Margin | 4.44% | 6.18% | -19.89% | -4.31% | -0.38% | -17.88% |
Profit Margin | 0.68% | 39.36% | 43.32% | -1.72% | 2.20% | -11.81% |
Free Cash Flow Margin | -8.97% | 4.60% | -3.94% | -8.38% | 1.18% | 9.42% |
EBITDA | 35.81 | 46.24 | -54.19 | -0.58 | 10.05 | -36.18 |
EBITDA Margin | 7.43% | 8.61% | -16.29% | -0.18% | 4.14% | -13.38% |
D&A For EBITDA | 14.42 | 13.07 | 12.01 | 13.11 | 10.98 | 12.15 |
EBIT | 21.39 | 33.17 | -66.2 | -13.68 | -0.93 | -48.33 |
EBIT Margin | 4.44% | 6.18% | -19.89% | -4.31% | -0.38% | -17.88% |
Effective Tax Rate | 71.23% | 4.14% | - | - | 3.61% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.